Provided by Tiger Trade Technology Pte. Ltd.

Denali Therapeutics Inc.

23.31
-0.1800-0.77%
Post-market: 23.29-0.0200-0.09%18:35 EDT
Volume:2.52M
Turnover:59.31M
Market Cap:3.70B
PE:-8.10
High:24.65
Open:24.17
Low:23.21
Close:23.49
52wk High:24.65
52wk Low:12.58
Shares:158.59M
Float Shares:144.00M
Volume Ratio:1.30
T/O Rate:1.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8782
EPS(LYR):-2.9700
ROE:-49.59%
ROA:-26.95%
PB:3.99
PE(LYR):-7.85

Loading ...

Sector Update: Health Care

MT Newswires Live
·
Jun 18

Denali Therapeutics enters agreement to sell Rare Pediatric Disease PRV

TIPRANKS
·
Jun 18

Denali Therapeutics to sell rare pediatric disease priority review voucher for $195 million

Reuters
·
Jun 18

Denali Therapeutics - to Sell Rare Pediatric Disease Priority Review Voucher for $195 Mln

THOMSON REUTERS
·
Jun 18

Denali Therapeutics (DNLI) Receives a Buy from UBS

TIPRANKS
·
Jun 16

Denali Therapeutics shareholders elect three Class III directors at annual meeting

Reuters
·
Jun 04

Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick. -- Barrons.com

Dow Jones
·
Jun 03

A Look At Denali Therapeutics (DNLI) Valuation After Phase 2b Trial Failure Refocuses Attention On Its Pipeline

Simply Wall St.
·
May 30

Denali Therapeutics' Focus Shifts to Other Pipeline Assets After Phase 2b Study Failure, Morgan Stanley Says

MT Newswires Live
·
May 26

Analysts Are Bullish on Top Healthcare Stocks: Denali Therapeutics (DNLI), Intuitive Surgical (ISRG)

TIPRANKS
·
May 22

BUZZ-U.S. STOCKS ON THE MOVE-Estée Lauder, Perpetua Resources, Merck & Co

Reuters
·
May 22

Denali Therapeutics Shares Fall 7.3% Premarket After Scrapping Development of Parkinson's Drug

THOMSON REUTERS
·
May 22

Biogen, Denali Say Parkinson's Drug Didn't Meet Trial Endpoints -- Update

Dow Jones
·
May 22

Denali, Biogen scrap BIIB122 Parkinson’s program after Phase 2b LUMA miss

Reuters
·
May 22

Biogen and Denali Therapeutics Provide Update on Phase 2B Luma Study of Biib122 (Dnl151) in Early-Stage Parkinson’s Disease

THOMSON REUTERS
·
May 22

Biogen - Data From Beacon Study Anticipated in First Half of 2027

THOMSON REUTERS
·
May 22

Biogen - Biib122 Generally Well Tolerated With Acceptable Safety Profile

THOMSON REUTERS
·
May 22

Biogen - Denali Continues Phase 2a Beacon Study in Lrrk2 Variant Carriers

THOMSON REUTERS
·
May 22

Biogen - Phase 2B Luma Study of Biib122 Does Not Meet Primary or Secondary Endpoints

THOMSON REUTERS
·
May 22

Biogen - Co and Denali to Discontinue Development of Biib122 in Idiopathic Parkinson’s Disease

THOMSON REUTERS
·
May 22